MYOS RENS Technology Inc. (NASDAQ:MYOS) CEO Joseph Mannello acquired 16,819 shares of the company’s stock in a transaction dated Wednesday, December 6th. The stock was acquired at an average cost of $1.35 per share, for a total transaction of $22,705.65. Following the completion of the acquisition, the chief executive officer now directly owns 233,629 shares in the company, valued at $315,399.15. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Joseph Mannello also recently made the following trade(s):

  • On Friday, December 8th, Joseph Mannello acquired 38,119 shares of MYOS RENS Technology stock. The stock was acquired at an average cost of $1.35 per share, for a total transaction of $51,460.65.
  • On Tuesday, November 14th, Joseph Mannello acquired 11,750 shares of MYOS RENS Technology stock. The stock was acquired at an average cost of $1.27 per share, for a total transaction of $14,922.50.
  • On Thursday, November 16th, Joseph Mannello acquired 25,000 shares of MYOS RENS Technology stock. The stock was acquired at an average cost of $1.31 per share, for a total transaction of $32,750.00.

Shares of MYOS RENS Technology Inc. (NASDAQ:MYOS) remained flat at $$1.37 during midday trading on Friday. The company’s stock had a trading volume of 38,492 shares, compared to its average volume of 578,144. MYOS RENS Technology Inc. has a 52-week low of $1.02 and a 52-week high of $6.98.

MYOS RENS Technology (NASDAQ:MYOS) last announced its quarterly earnings results on Tuesday, November 14th. The company reported ($0.13) earnings per share (EPS) for the quarter. MYOS RENS Technology had a negative return on equity of 71.14% and a negative net margin of 941.41%. The firm had revenue of $0.16 million for the quarter.

Separately, ValuEngine raised shares of MYOS RENS Technology from a “strong sell” rating to a “sell” rating in a report on Wednesday, September 6th.

TRADEMARK VIOLATION WARNING: This piece was first posted by American Banking News and is the property of of American Banking News. If you are viewing this piece on another publication, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark legislation. The original version of this piece can be viewed at https://www.americanbankingnews.com/2017/12/08/insider-buying-myos-rens-technology-inc-myos-ceo-buys-16819-shares-of-stock.html.

About MYOS RENS Technology

MYOS RENS Technology Inc (MYOS), formerly MYOS Corporation, is an early-stage bionutrition and biotherapeutics company. The Company is focused on the discovery, development and commercialization of products that improve muscle health and function essential for the management of sarcopenia, cachexia and degenerative muscle diseases, and as an adjunct to the treatment of obesity.

Receive News & Ratings for MYOS RENS Technology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MYOS RENS Technology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.